ArticleNature communications2022

The engineered CD80 variant fusion therapeutic davoceticept combines checkpoint antagonism with conditional CD28 costimulation for anti-tumor immunity.

Mark F Maurer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.